top of page

Sage will be attending BioEurope 2026 from 9-11 November in Cologne and would be pleased to meet you!

ChatGPT Image Jan 14, 2026, 03_17_04 PM.png

Eurofins Discovery Announces Aquisition of Sage Client Discovery BioMed

Jul 5, 2022

1 min read

Updated: Jan 29, 2023

See full Press Release by clicking the link below!

Comments

Featured Posts

Check back soon

Once posts are published, you’ll see them here.

Recent Posts

Sage Advises PolyPid on Exclusive U.S. and Canadian Commercial Partnership with Azurity Pharmaceuticals for D-PLEX100

Respien Appoints Sage to Lead Global Partnering Process for HI-164, a Phase 3-Ready COPD Therapy

Sage Advises Hatchtech on Pelthos Therapeutics Acquisition of Xeglyze® (abametapir) Topical Treatment for Head Lice

Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults

Serpin Pharma Partners with Dogwood Therapeutics to Develop and Commercialize SP16 as a Treatment for Cancer-Related Pain

Sage Group Advises Fabre-Kramer Pharma on Partnering Deal with Aytu Biopharma for EXXUA(TM), a Newly Approved and Innovative Treatment for Major Depressive Disorder

Sage New Client: Notogen's Groundbreaking Regenerative Therapy for Degenerative Disc Disease

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Opportunity to License XMVA09, A Phase I First-in-class Intravitreal AAV Therapy Expressing Anti-VEGF and ANG2 Bispecific Antibody

Opportunity to License SP16, A Novel Treatment For Acute Kidney Injury (AKI)

Archive

Search By Tags

Follow Us

bottom of page